About:
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Its product portfolio include ALEXIS AIDT-1, an allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, an allogenic CAR cell product candidate targeting AIDT-2; ALEXIS AIDT-2 MPM (malignant pleural mesothelioma), an allogenic CAR/NKT-Like cell product candidate targeting AIDT-2; and PD-1-AR, a check point inhibitor for solid tumors, as well as oral healthcare products, such as mouthwash. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Sector:
HealthcareIndustry:
BiotechnologyEmployees:
19Address:
Kiromic BioPharma, Inc. 7707 Fannin Suite 140 Houston TX 77054 United StatesWebsite:
Home